Cardiovascular Diagnostics forms holding company:
This article was originally published in Clinica
Executive Summary
Cardiovascular Diagnostics' shareholders have approved a holding company reorganisation, which sees Cardiovascular becoming a wholly-owned subsidiary of the new holding company, PharmaNetics. Each share of Cardiovascular has been converted into PharmaNetics shares, which will be traded on the Nasdaq. No changes have been made to the company's management or board of directors. The Raleigh, North Carolina-based company makes rapid diagnostics to assess blood clot formation and dissolution.